'Composite endpoint' presentation slideshows

Composite endpoint - PowerPoint PPT Presentation

Dalteparin ( Fragmin ? ) NDA 20-287 S-035

Dalteparin ( Fragmin ? ) NDA 20-287 S-035

Dalteparin ( Fragmin ? ) NDA 20-287 S-035 . FDA Oncologic Drugs Advisory Committee Meeting September 6, 2006. Introduction. Connie Newman, M.D. Executive Director Worldwide Regulatory Affairs Pfizer Inc. Proposed Indication Dalteparin sNDA 20-287 S-035.

★ ★ ★ ★ ★

1.41k views • 80 slides
Do T irofiban A nd R eoPro G ive Similar E fficacy Outcomes T rial

Do T irofiban A nd R eoPro G ive Similar E fficacy Outcomes T rial

Do T irofiban A nd R eoPro G ive Similar E fficacy Outcomes T rial. N Engl J Med 2001;344:1888-94. GP IIb/IIIa Inhibition in PCI. Consistent reduction in adverse events Optimal outcome when combined with stents No comparative data between agents. 0.0. 0.5. 1.0. 2.0. Background.

★ ★ ★ ★ ★

530 views • 43 slides
Panel Questions-Clinical Trial Design

Panel Questions-Clinical Trial Design

Panel Questions-Clinical Trial Design. 1. Can the data from the investigator-sponsor studies be considered in the evaluation of high risk stenting given the differences in trial conduct for the high-risk investigator-sponsor registries?. Panel Questions-Clinical Trial Design.

★ ★ ★ ★ ★

408 views • 17 slides
Presented at The European Society of Cardiology Scientific Congress 2006

Presented at The European Society of Cardiology Scientific Congress 2006

FRISC II Trial. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease (FRISC II): Five-Year Follow-up of the FRISC-II Invasive Study. Presented at The European Society of Cardiology Scientific Congress 2006 Presented by Dr. Bo Lagerqvist.

★ ★ ★ ★ ★

304 views • 8 slides
Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial. Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA. Am Heart J. 2003 Aug;146(2):304-10. EVET.

★ ★ ★ ★ ★

239 views • 7 slides
Discontinuation of medication after nonfatal event: MI

Discontinuation of medication after nonfatal event: MI

Discontinuation of medication after nonfatal event: MI. 0.5. Component of composite endpoint Myocardial I nfarction. 0.4. No event. With event. 0.3. Proportion of patients stopping medication. 0.2. 0.1. 0. 360. 720. 1080. 1440. 1800. 2180. Days of follow up.

★ ★ ★ ★ ★

73 views • 2 slides
Cardio-Sis

Cardio-Sis

Cardio-Sis. Incidence of LVH was lower with tight control over usual control (11.4% vs. 17.0% ) Composite (death, MI, stroke, TIA, CHF, angina, new AF, revascularization, aortic dissection, PAD, ESRD) was lower with tight control Adverse events, including hypotension, were similar.

★ ★ ★ ★ ★

236 views • 1 slides

View Composite endpoint PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Composite endpoint PowerPoint presentations. You can view or download Composite endpoint presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.